Company intelligence / Profile preview

EmbarkNeuro

Oakland, California, United Statesembarkneuro.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

EmbarkNeuro is conducting a Phase 2 trial of ANC-501, a first-in-class vasopressin 1b (V1b) receptor antagonist for the treatment of major depressive disorder. The first patient was dosed in November 2022 in an 8-week single-arm trial assessing the efficacy of ANC-501 when added to standard antidepressant therapy in patients with biomarker-confirmed disruption in their stress-response system[4].

Therapeutic areas: Psychiatry
Modalities: Small molecules (V1b receptor antagonist)
Industry: Biotech

Drug pipeline

1 asset

ANC-501

Partnerships

Taisho Pharmaceutical Co., Ltd. (in-licensed ANC-501)[3]

Beyond the preview

Go deeper on EmbarkNeuro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EmbarkNeuro.

Explore the full profile